Effects of Colesevelam HCl On Bile Acid Kinetics
Completed
Conditions studied: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
In brief
This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes. We hypothesize that bile acids will behave differently in these groups. We will also explore the effects of Colesevelam HCl, a medicine that lowers LDL cholesterol by binding bile acids, on bile acids in those groups. We hypothesize the drug may have different actions on bile acids in subjects with different degrees of abnormal glucose metabolism.
Key facts
- Study ID
- NCT00476710
- Run by
- KineMed
- People needed
- 36
- Starts
- 2007-05-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2015-04-01
Who can join
Age: 40 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Have given written informed consent
- BMI 25-35 kg/m\^2, inclusive
- Normal liver and thyroid function
- No history of liver, biliary, or intestinal disease
- Diabetic Subjects
- Diagnosed Type 2 Diabetes Mellitus
- HbA1C = 6.7-10%
- Normal Subjects
- 2 hr OGTT glucose < 140 mg/dL
- fasting glucose < 100 mg/dL
- TG < 150 mg/dL
- HDL cholesterol >= 40 mg/dL
- Impaired Glucose Tolerance Subjects
- 2 hr OGTT glucose >= 140 and < 200 mg/dL
You may not qualify if…
- T1DM or history of diabetic ketoacidosis
- treatment with blood pressure lowering therapy that has not been stable for three months before screening
- colesevelam HCl, cholestyramine, or colestipol treatment for hyperlipidemia within the last three months
- treatment with thiazolidinedione (TZD) at any time
- treatment with insulin within past 6 months
- treatment with antibiotics within last 3 months
- extreme sportsmen
- treatment with medication affecting liver or intestinal function within the last 3 months
- allergic or toxic rxn to colesevelam HCl
- history of dysphagia, swallowing disorders, or intestinal motility disorder
- Serum Triglycerides > 500 mg/dL at visit 1
- Serum LDL-C < 60 mg/dL at visit 1
- any condition or therapy investigator believes not in subjects best interest
- use of any investigational drug within 30 days before screening
- chronic treatment with oral corticosteroids at any time or acute treatment within last three months
- hyperthyroidism or treatment with thyroid hormone/levothyroxine
Where it is running
- Diabetes & Glandular Disease Research Associates, Inc. — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.